Innovations in immunotherapy: How CAR T-cell therapy is changing cancer treatment
Introduction
Recent innovations in CAR T-cell therapy are giving new hope to patients whose cancer has not responded to other treatments. By harnessing the power of the immune system in a highly personalised way, this approach is opening up new treatment options at a stage where choices may otherwise be limited.
CAR T-cell therapy is most commonly used in people with myeloma and lymphoma that has returned after previous treatment (called relapsed disease) or has not responded to standard therapies (called refractory disease).
At our specialist cancer centres, patients can now access CAR T-cell therapy through dedicated care pathways delivered by experienced clinical teams. With expert guidance, careful monitoring and personalised treatment planning, this complex therapy can be delivered safely and effectively for those who may benefit from it.
What are CAR T cells?
To understand CAR T-cell therapy, it helps to start with T cells and how the immune system normally works.
T cells are a type of white blood cell that play a central role in protecting your body. They are constantly scanning for signs of infection or abnormal cells, including cancer. When they recognise a threat, they can attach to it and destroy it.
However, cancer cells are often able to avoid detection. They can reduce the signals that immune cells rely on or create an environment that prevents T cells from working properly. This is one of the reasons why cancer can continue to grow despite the body’s natural defences.
CAR T cells are designed to overcome this problem.
In CAR T-cell therapy, your own T cells are collected and reprogrammed in a laboratory to produce a new structure on their surface called a chimeric antigen receptor, or CAR. This receptor is designed to recognise a specific protein found on cancer cells.
Because the cells are made from your own immune system, this approach is highly personalised. It is tailored not only to the type of cancer but also to your individual biology.
How are CAR T cells created?
CAR T-cell therapy is not a standard drug that can be prescribed immediately. It is a carefully coordinated, multi-step process that requires specialist expertise, advanced laboratory technology and close collaboration between clinical teams.
Collecting cells
The process begins with the collection of your T cells using a procedure called apheresis. Blood is taken through a tube, passed through a machine that separates out the T cells, and then returned to your body.
This is usually carried out as an outpatient procedure and is managed by experienced teams who specialise in cellular therapies.
Reprogramming the cells
The collected T cells are then sent to a specialist laboratory, where they are genetically modified.
Scientists introduce new genetic material into the cells, often using a harmless viral vector. This genetic change instructs the T cells to produce the CAR receptor on their surface.
This step is highly precise and requires strict quality controls to ensure the cells function as intended.
Expanding the cells
Once modified, the CAR T cells are multiplied in the laboratory to create millions of copies. This expansion phase is essential to ensure there are enough cells to mount an effective response once they are returned to your body.
This stage can take several weeks and is carefully monitored throughout.
Quality testing and co-ordination
Before the cells are ready to be used, they undergo rigorous testing to confirm their safety, purity and effectiveness.
During this time, your clinical team will continue to support you, and in some cases may recommend additional treatment to help control the cancer while the CAR T cells are being prepared.
Because of the complexity of this process, access to CAR T-cell therapy is typically through specialist centres with established cellular therapy programmes and experienced multidisciplinary teams.
What is the science behind CAR T-cell therapy?
The science behind CAR T-cell therapy lies in improving how the immune system recognises and responds to cancer.
Why the immune system needs help
Under normal conditions, T cells detect abnormal cells by recognising proteins, or antigens, on their surface. However, cancer cells can evade this process by altering or hiding these signals.
They may also create a suppressive environment that reduces the activity of immune cells. This means that even when T cells are present, they may not be able to respond effectively.
CAR T-cell therapy is designed to overcome these challenges.
How the CAR receptor works
The chimeric antigen receptor is an engineered structure that combines several functional elements into a single receptor.
One part of the receptor is designed to recognise a specific protein on the cancer cell. Another part sends an activation signal to the T cell when that target is found.
This allows CAR T cells to recognise cancer cells directly, without relying on the usual immune pathways that cancer may have disrupted.
What happens when CAR T cells find cancer
When a CAR T cell binds to its target, several things happen.
The T cell becomes activated and releases substances that kill the cancer cell. At the same time, it sends signals to recruit other immune cells, strengthening the overall immune response.
The activated T cell also begins to multiply, increasing the number of cancer-fighting cells in the body.
Expansion and persistence
One of the most important features of CAR T-cell therapy is that the cells can continue to expand inside the body after they are given.
This means the treatment is not limited to the initial number of cells infused. Instead, it can grow into a larger and more sustained immune response over time.
Some CAR T cells can also persist in the body long term. This allows them to continue monitoring for cancer cells and respond if they return.
A sustained and active immune response
Unlike many traditional cancer treatments, which act for a limited period of time, CAR T-cell therapy can continue working in the body after it has been given.
The modified T cells remain active, allowing them to keep recognising and responding to cancer cells over time. In some cases, these cells can persist in the body for months or even years, continuing to provide ongoing immune surveillance.
This ability to remain active and responsive is one of the reasons why CAR T-cell therapy has shown the potential for deep and long-lasting responses in some patients.
At experienced centres, patients are closely monitored throughout this process, with specialist teams trained to manage both the treatment and any side effects that may occur.
Enquire today
Contact us today to arrange a consultation and find out more about accessing CAR T-cell therapy through our specialist centres, please call 0808 304 2332 or complete the enquiry form.
Access to expert care
Because CAR T-cell therapy is complex and highly specialised, it is important that it is delivered within a dedicated cellular therapy programme.
Specialist centres bring together haematology experts, oncology teams, nurses and support staff who are experienced in every stage of the treatment, from assessment and cell collection through to follow-up care.
These teams work closely with leading institutions and laboratories to ensure patients can access the most advanced therapies available, supported by robust safety protocols and personalised care pathways.
Is CAR T-cell therapy right for you?
CAR T-cell therapy may be an option for people whose cancer has returned after treatment or has not responded to standard therapies.
If you would like to understand whether this treatment could be suitable for you, speaking to our specialist team is an important first step.
By seeking expert advice, you can explore your options, understand the potential benefits and risks, and receive a personalised recommendation based on your individual situation.
Contact us
Call us today: 0808 304 2332
Professor Karthik Ramasamy, MBBS, PhD, FRCP, FRCPath
Consultant Haematologist
